Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study

Research output: Contribution to journal › Journal article › Research › peer-review

  • Hans-Jürgen Stellbrink
  • Chloe Orkin
  • Jose Ramon Arribas
  • Juliet Compston
  • Gerstoft, Jan
  • Eric Van Wijngaerden
  • Adriano Lazzarin
  • Giuliano Rizzardini
  • Herman G Sprenger
  • John D. C. Lambert
  • Gunta Sture
  • David Leather
  • Sara Hughes
  • Patrizia Zucchi
  • Helen Pearce
  • ASSERT Study Group
Abacavir-lamivudine and tenofovir DF-emtricitabine fixed-dose combinations are commonly used as first-line antiretroviral therapies. However, few studies have comprehensively compared their relative safety profiles.
Original languageEnglish
JournalClinical Infectious Diseases
Volume51
Issue number8
Pages (from-to)963-72
Number of pages10
ISSN1058-4838
DOIs
Publication statusPublished - 15 Oct 2010

ID: 34052069